Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2026
Event: Unregistered sales of equity securities via conversion of debt held by the Chairman of the Board.
Key Financial Metrics and Transaction Details
- Debt Converted: $91.0 million in aggregate principal and approximately $14.8 million in accrued interest (Total: ~$105.8 million).
- Shares Issued: 34,376,167 shares of Common Stock.
- Conversion Price: Blended average of approximately $3.07 per share (subject to a $3.00 floor price).
- Outstanding Equity Post-Conversion: Approximately 100,849,644 shares of Common Stock and 197,500 shares of Series A Voting Preferred Stock.
- Remaining Credit Facility: A $10.0 million supplemental line of credit (dated December 19, 2025) remains undrawn and available.
Material Changes Versus Prior Period
The filing reports a significant reduction in debt obligations and a corresponding increase in equity capitalization. The conversion eliminated approximately $105.8 million in liabilities owed to Richard E. Uihlein, the Company's Chairman and largest stockholder. This transaction increased Mr. Uihlein's beneficial ownership to approximately 44.3% of outstanding voting power on an actual basis, and approximately 49.3% when including shares issuable upon exercise of outstanding warrants.
Guidance, Outlook, and Regulatory Matters
- Registration Rights: The Company is obligated to register the resale of the newly issued shares within 180 days of the conversion date.
- Exemption: The issuance was exempt from registration under Section 3(a)(9) of the Securities Act as it involved an exchange of securities with existing holders without commission.
- Restrictions: The issued shares are subject to resale restrictions until registered.
- Financial Outlook: The filing text does not provide specific revenue, profit, cash flow, or margin guidance. It does not disclose general operational risks or contingencies beyond the transaction details.
Investor Verification Checklist
- Verify the impact of the $105.8 million debt elimination on the Company's balance sheet and interest expense.
- Confirm the dilution effect of issuing 34.4 million new shares on existing shareholders.
- Review the terms of the remaining $10.0 million undrawn credit facility for future liquidity needs.
- Monitor the Company's compliance with the 180-day registration right obligation for the new shares.
- Assess the concentration of voting power held by Mr. Uihlein (approx. 49.3% including warrants).